Deep Vein Thrombosis in Europe-Health-Related Quality of Life and Mortality
Por:
Monreal, M, Agnelli, G, Chuang, LH, Cohen, AT, Gumbs, PD, Bauersachs, R, Mismetti, P, Gitt, AK, Kroep, S, Willich, SN and Van Hout, B
Publicada:
20 nov 2019
Resumen:
Objectives: Deep vein thrombosis (DVT) is a major health-care burden in Europe, but exact estimates are lacking. This study reports results from the PREFER venous thromboembolism (VTE) study concerning health-related quality of life (HrQoL) and mortality of patients with DVT. Methods: PREFER VTE was a prospective, observational study, conducted in 7 European countries, designed to provide data concerning treatment patterns, resource utilization, mortality, and QoL. First-time or recurrent patients with DVT were followed at 1, 3, 6, and 12 months. Health-related QoL-as measured by the EuroQoL 5-Dimension 5-Level instrument ( EQ-5D-5L)-was analyzed using Tobit regression with repeated measures, assessing the impact of baseline characteristics stratified by cancer activity. Mortality was analyzed using logistic regression. Results: At baseline, patients with DVT had a 0.14 lower EQ-5D-5L index score (0.72 for total sample) compared to the reference UK population (0.85). The EQ-5D-5L index score improved from baseline to 12 months in patients with active cancer (from 0.70 to 0.79) and those without (0.72-0.87); 7.3% died within a year, a 5.2% excess mortality compared to the age- and gender-adfjusted general population. The 12-month mortality rate of DVT varied between 2.9% in the pooled data from Germany, Switzerland, or Austria and 15.4% in Italy. Furthermore, the mortality rate differed between patients with active cancer and those without (42.9% vs 4.7%). Conclusions: Deep vein thrombosis is associated with a substantial burden of illness in terms of HrQoL at baseline, which following treatment normalizes after 12 months and has a significant mortality rate. In addition, active cancer has a significant impact on mortality and the HrQoL of patients with DVT.
Filiaciones:
:
Hosp Badalona Germans Trias & Pujol, Barcelona, Spain
Agnelli, G:
Univ Perugia, Perugia, Italy
Chuang, LH:
Pharmerit Int, Rotterdam, Netherlands
Cohen, AT:
Guys & St Thomas NHS Fdn Trust, London, England
Gumbs, PD:
Dauchi Sankyo Europe GmbH, Munich, Germany
Bauersachs, R:
Klinikum Darmstadt, Dept Vasc Med, Darmstadt, Germany
Mismetti, P:
CHU St Etienne, Hosp Nord, St Etienne 2, France
Gitt, AK:
Herzzentrum Ludwigshafen, Ludwigshafen, Germany
Kroep, S:
Pharmerit Int, Rotterdam, Netherlands
Willich, SN:
Charite Univ Med Berlin, Berlin, Germany
Van Hout, B:
Univ Sheffield, Sheffield, S Yorkshire, England
Green Accepted, Green Published, gold
|